share_log

Healthcare of Ontario Pension Plan Trust Fund Reduces Stake in Balchem Co. (NASDAQ:BCPC)

Healthcare of Ontario Pension Plan Trust Fund Reduces Stake in Balchem Co. (NASDAQ:BCPC)

安大略省養老金計劃信託基金的醫療保健減持Balchem Co.(納斯達克股票代碼:BCPC)
Defense World ·  2022/09/08 06:32

Healthcare of Ontario Pension Plan Trust Fund cut its stake in shares of Balchem Co. (NASDAQ:BCPC – Get Rating) by 74.8% during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 10,700 shares of the basic materials company's stock after selling 31,800 shares during the period. Healthcare of Ontario Pension Plan Trust Fund's holdings in Balchem were worth $1,463,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

安大略省養老金計劃信託基金的Healthcare在提交給美國證券交易委員會(SEC)的最新Form 13F文件中稱,該公司第一季度將所持Balchem Co.(納斯達克:BCPC-GET Rating)的股份削減了74.8%。在此期間,該公司出售了31,800股基礎材料公司的股票,持有10,700股。截至安大略省養老金計劃信託基金最近提交給美國證券交易委員會(SEC)的文件,安大略省養老金計劃信託基金持有的Balchem醫療保健股份價值1,463,000美元。

Several other institutional investors have also modified their holdings of BCPC. Intelligent Financial Strategies bought a new stake in Balchem in the fourth quarter worth $25,000. UMB Bank N A MO purchased a new position in shares of Balchem during the 4th quarter worth about $56,000. Carolinas Wealth Consulting LLC grew its holdings in Balchem by 130.5% during the 4th quarter. Carolinas Wealth Consulting LLC now owns 484 shares of the basic materials company's stock valued at $82,000 after purchasing an additional 274 shares during the last quarter. First Horizon Advisors Inc. lifted its stake in Balchem by 43.1% in the fourth quarter. First Horizon Advisors Inc. now owns 558 shares of the basic materials company's stock worth $93,000 after purchasing an additional 168 shares during the last quarter. Finally, Destiny Wealth Partners LLC boosted its position in shares of Balchem by 58.4% during the first quarter. Destiny Wealth Partners LLC now owns 659 shares of the basic materials company's stock valued at $90,000 after buying an additional 243 shares during the period. 89.15% of the stock is owned by institutional investors.

其他幾家機構投資者也調整了對BCPC的持股。Smart Financial Strategy在第四季度購買了Balchem價值2.5萬美元的新股份。UMB Bank N A MO在第四季度購買了Balchem的新頭寸,價值約56,000美元。Carolinas Wealth Consulting LLC在第四季度增持了130.5%的Balchem股份。Carolinas Wealth Consulting LLC現在持有這家基礎材料公司484股股票,價值82,000美元,上個季度又購買了274股。First Horizon Advisors Inc.在第四季度增持了43.1%的Balchem股份。First Horizon Advisors Inc.現在持有這家基礎材料公司558股股票,價值93,000美元,該公司在上個季度又購買了168股。最後,Destiny Wealth Partners LLC在第一季度將其在Balchem的股票頭寸增加了58.4%。Destination Wealth Partners LLC現在擁有這家基礎材料公司659股股票,價值9萬美元,在此期間又購買了243股。89.15%的股份由機構投資者持有。

Get
到達
Balchem
巴爾切姆
alerts:
警報:

Balchem Trading Up 3.1 %

Balchem交易上漲3.1%

Shares of NASDAQ BCPC opened at $134.35 on Thursday. Balchem Co. has a twelve month low of $110.15 and a twelve month high of $174.29. The firm has a market cap of $4.32 billion, a PE ratio of 40.22 and a beta of 0.59. The business has a fifty day simple moving average of $131.75 and a two-hundred day simple moving average of $129.99. The company has a quick ratio of 1.64, a current ratio of 2.62 and a debt-to-equity ratio of 0.50.

週四,納斯達克BCPC的股價開盤報134.35美元。Balchem Co.股價跌至110.15美元的12個月低點,以及174.29美元的12個月高點。該公司市值為43.2億美元,市盈率為40.22倍,貝塔係數為0.59。該業務的50日簡單移動均線切入位為131.75美元,200日簡單移動均線切入位為129.99美元。該公司的速動比率為1.64,流動比率為2.62,債務權益比率為0.50。

Wall Street Analyst Weigh In

華爾街分析師也加入進來

A number of equities research analysts recently issued reports on the company. StockNews.com lowered Balchem from a "buy" rating to a "hold" rating in a research note on Monday, August 1st. HC Wainwright boosted their target price on shares of Balchem from $152.00 to $164.00 and gave the company a "buy" rating in a research note on Monday, August 22nd.
一些股票研究分析師最近發佈了關於該公司的報告。在8月1日星期一的一份研究報告中,StockNews.com將Balchem的評級從“買入”下調至“持有”。8月22日,週一,HC Wainwright在一份研究報告中將Balchem的股票目標價從152.00美元上調至164.00美元,並對該公司進行了“買入”評級。

Insider Buying and Selling

內幕買賣

In other news, VP Gunsteren Job Leonard Van sold 3,601 shares of the business's stock in a transaction dated Wednesday, August 3rd. The shares were sold at an average price of $125.62, for a total value of $452,357.62. Following the completion of the sale, the vice president now owns 1,430 shares in the company, valued at approximately $179,636.60. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. 1.60% of the stock is owned by insiders.

在其他新聞方面,副總裁岡斯特倫·約伯·倫納德·範在8月3日星期三的一筆交易中出售了3601股該公司的股票。這些股票的平均價格為125.62美元,總價值為452,357.62美元。出售完成後,副總經理總裁現在擁有該公司1,430股股份,價值約179,636.60美元。這筆交易是在提交給美國證券交易委員會的一份文件中披露的,該文件可以在美國證券交易委員會網站上找到。1.60%的股份由內部人士持有。

Balchem Profile

Balchem配置文件

(Get Rating)

(獲取評級)

Balchem Corporation develops, manufactures, and markets specialty performance ingredients and products for the nutritional, food, pharmaceutical, animal health, medical device sterilization, plant nutrition, and industrial markets in the United States and internationally. It operates through three segments: Human Nutrition & Health, Animal Nutrition & Health, and Specialty Products.

Balchem公司為美國和國際的營養、食品、製藥、動物保健、醫療器械消毒、植物營養和工業市場開發、製造和銷售特殊性能成分和產品。它通過三個部分運作:人類營養與健康,動物營養與健康,以及特色產品。

Featured Stories

專題報道

  • Get a free copy of the StockNews.com research report on Balchem (BCPC)
  • 3 High Margin Chipmakers Bound to Recover
  • 3 Solar Stocks That Will Benefit From the Biden Tariff Holiday
  • REV Group Has A Deep Moat In The World Of EVs
  • Is G-III Apparel Group, Ltd. A Value Trap?
  • Bank Of America Sees Upside In These 2 European Alcohol Stocks
  • 免費獲取StockNews.com關於Balchem的研究報告(BCPC)
  • 3家高利潤率芯片製造商勢必復甦
  • 將受益於拜登關税假期的3只太陽能股
  • REV集團在電動汽車世界擁有深厚的護城河
  • G-III服裝集團有限公司是價值陷阱嗎?
  • 美國銀行看好這兩隻歐洲酒類股票

Receive News & Ratings for Balchem Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Balchem and related companies with MarketBeat.com's FREE daily email newsletter.

接受Balchem Daily的新聞和評級-在下面輸入您的電子郵件地址,通過MarketBeat.com的免費每日電子郵件時事通訊接收對Balchem和相關公司的最新新聞和分析師評級的每日簡要摘要。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論